No matches
Type 2 Inflammation

Type 2 Inflammatory Disease: What Are the Mechanisms that Contribute to the Development of Other Atopic Comorbidities?

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares explains how type 2 inflammation and barrier dysfunction contribute to the development of atopic comorbidities and increased susceptibility to infections.
Oscar Palomares
PhD
Oscar Palomares

Related resources

Managing Type 2 Inflammatory Diseases: Multidisciplinary Frame of Mind

Managing Type 2 Inflammatory Diseases: Multidisciplinary Frame of Mind

expert video
Clinical Manifestations Associated With Airway Remodeling in Asthma

Clinical Manifestations Associated With Airway Remodeling in Asthma

expert video
Impact of Exacerbations in COPD

Impact of Exacerbations in COPD

expert video
Role of Type 2 Cytokines in Asthma and COPD

Role of Type 2 Cytokines in Asthma and COPD

expert video
Exacerbations Lead to Worsening Lung Function

Exacerbations Lead to Worsening Lung Function

expert video
Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

expert video
Mucus Plugging as a Potential Target in Asthma Management

Mucus Plugging as a Potential Target in Asthma Management

expert video
Multifaceted Role of IL-13 in Airway Remodeling

Multifaceted Role of IL-13 in Airway Remodeling

expert video
Pediatric Asthma Trajectory and Clinical Remission

Pediatric Asthma Trajectory and Clinical Remission

expert video
2025 ADVENT Forum | Joint Plenary Session: A View into the Life of Our Patients Video

2025 ADVENT Forum | Joint Plenary Session: A View into the Life of Our Patients Video

expert video
The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis

The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis

expert video
AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

videoanimation
EAACI 2025 | At The Intersection of the Type 2 Airways: Navigating the Challenges of CRSwNP & Co-existing Asthma

EAACI 2025 | At The Intersection of the Type 2 Airways: Navigating the Challenges of CRSwNP & Co-existing Asthma

expert video
EAACI PAAM 2025 | How Type 2 Inflammation Shapes a Lifetime

EAACI PAAM 2025 | How Type 2 Inflammation Shapes a Lifetime

expert video
The Role of IL-4 and IL-13 in CSU Pathogenesis

The Role of IL-4 and IL-13 in CSU Pathogenesis

interactivity
IL-4 Is the Primary Cytokine That Drives Th2 Cell Polarization and Amplifies Type 2 Inflammation

IL-4 Is the Primary Cytokine That Drives Th2 Cell Polarization and Amplifies Type 2 Inflammation

expert video
How Does Type 2 Inflammation Manifest in Chronic Diseases Across Different Organs?

How Does Type 2 Inflammation Manifest in Chronic Diseases Across Different Organs?

expert video
Type 2 Inflammatory Diseases Can Negatively Impact Patients and Their Caregivers

Type 2 Inflammatory Diseases Can Negatively Impact Patients and Their Caregivers

expert video
Distinct Mechanisms Drive Inflammation and Itch in Chronic, Type 2 Inflammatory Diseases

Distinct Mechanisms Drive Inflammation and Itch in Chronic, Type 2 Inflammatory Diseases

expert video
Coexisting Type 2 Inflammatory Diseases Can Add to the Patient Overall Disease Burden

Coexisting Type 2 Inflammatory Diseases Can Add to the Patient Overall Disease Burden

expert video
Itch in Chronic Inflammatory Skin Diseases: Histaminergic and Nonhistaminergic Mechanisms and Role of IL-4 as a Central Orchestrator in Promoting Neuronal Sensitization

Itch in Chronic Inflammatory Skin Diseases: Histaminergic and Nonhistaminergic Mechanisms and Role of IL-4 as a Central Orchestrator in Promoting Neuronal Sensitization

expert video
In Chronic Pruritic Skin Diseases, the Neuroimmune Axis Involves Dynamic Interactions Between Type 2 Inflammation and Sensory Nerves

In Chronic Pruritic Skin Diseases, the Neuroimmune Axis Involves Dynamic Interactions Between Type 2 Inflammation and Sensory Nerves

expert video
From Protective Type 2 Immunity to Aberrant Type 2 Inflammation

From Protective Type 2 Immunity to Aberrant Type 2 Inflammation

expert video
Underlying Type 2 Inflammation Drives a Chronic Itch-Scratch Cycle in Atopic Dermatitis

Underlying Type 2 Inflammation Drives a Chronic Itch-Scratch Cycle in Atopic Dermatitis

expert video

Learning objectives

  • Describe how type 2 cytokines disrupt epithelial barriers and promote allergen sensitization that may lead to atopic comorbidities
  • Examine mechanisms linking type 2 inflammation to impaired innate immune responses and heightened vulnerability to viral infections
  • Recognize how early-life barrier dysfunction in atopic dermatitis may influence the trajectory of comorbid atopic diseases
Tags
expert insightsmechanism of disease
MAT-GLB-2507496 - 1.0 - 01/2026

About this expert

Allergy/Immunology

Oscar Palomares

PhD

Complutense University of Madrid

See author’s profile
Oscar Palomares

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BrazilChange country/region